Supposedly addicts make great repeat customers, but unfortunately for Reckitt Benckiser (OTC:RBGLY), they (or at least insurers and pharmacies) are quite price sensitive. That seems to be one of the underlying reasons behind the consumer brand giant’s recent announcement of plans to spin off its pharmaceuticals business. The majority of the units’ $1.3b in revenues come from sales of… Read More »
GlaxoSmithKline’s (GSK) CEO Sir Andrew Witty recently sat down with the Financial Times and the discussion included some talk about the future of its consumer health business. Although Mr. Witty mentioned that he is open to the idea of a spinoff at some point, the company was not currently pursuing the idea. There has been some spinoff speculation… Read More »
With the $2.1b sale of Red Lobster to private equity firm Golden Gate Capital all wrapped up, the battle for Darden (DRI) has officially entered the next phase. For a quick and abridged refresher on the situation, the ailing restaurant company was recently assailed by two activist firms pushing for numerous changes including a spinoff of its slower growing restaurants, Red Lobster… Read More »